IP Library › Granted Patent US 9,102,730
Granted Patent B2
US 9,102,730 · App. 13/872,793 · Granted Aug 11, 2015

Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells

Inventors: Gerard Zurawski (Midlothian, TX); Jacques F. Banchereau (Montclair, NJ); Eynav Klechevsky (Haifa, IL); Sandra Zurawski (Midlothian, TX); Anne-Laure Flamar (Dallas, TX)
Assignee: Baylor Research Institute
C07K16/2851A61K39/02A61K39/12A61K47/48746A61K47/48776B82Y5/00C12N5/0639A61K2039/505C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,730
App. No.
13/872,793
Granted
Aug 11, 2015
Kind
B2
Abstract

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Claims (8)

1. A method for eliciting an immune response against an antigen comprising contacting antigen presenting cells with a composition comprising an antibody-antigen complex having a Dendritic Cell Immunoreceptor (DCIR)-specific antibody, or DCIR-binding fragment thereof, attached to an antigen, wherein an immune response against the antigen is elicited.

2. The method of claim 1 , wherein DCIR-specific antibody or fragment thereof is bound to one half of a Cohesin/Dockerin pair.

3. The method of claim 1 , wherein DCIR-specific antibody or fragment thereof is bound to one half of a Cohesin/Dockerin pair and the antigen is bound to the complementary half of the Cohesin/Dockerin pair to form the complex.

4. The method of claim 1 , wherein the antigen is a bacterial, viral, fungal, or protozoan antigen.

5. The method of claim 1 , wherein the composition further comprises an adjuvant.

6. The method of claim 1 , wherein the antigen presenting cells are dendritic cells.

7. The method of claim 1 , wherein the antigen presenting cells are contacted with the composition by administering the composition to a patient.

8. The method of claim 1 , wherein the antigen is a Mycobacterium tuberculosis antigen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2014
From: KLECHEVSKY, EYNAV; ZURAWSKI, SANDRA; FLAMAR, ANNE-LAURE
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032232/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2014
From: ZURAWSKI, GERARD; BANCHEREAU, JACQUES
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032232/0285 →
Continuity (4)
Continuation 13234914 · Sep 16, 2011
Continuation 12024897 · Feb 1, 2008
Provisional Application 60888032 · Feb 2, 2007
Related Publication 20130295120A1 · Nov 7, 2013